JIM CRAMERBe Prepared: Cramer's 'Mad Money' Recap (Monday 12/9/19)By Scott RuttDec 9, 2019 8:46 PM EST
PRESS RELEASESExelixis Announces Partner Takeda Receives Approval In Japan For CABOMETYX® (cabozantinib) Tablets For The Treatment Of Curatively Unresectable Or Metastatic Renal Cell CarcinomaBy Business WireMar 25, 2020 3:01 AM EDT
PRESS RELEASESExelixis Announces George A. Scangos, Ph.D. To Retire From Its Board Of DirectorsBy Business WireMar 2, 2020 4:05 PM EST
PRESS RELEASESExelixis Announces Webcasts Of Investor Conference Presentations In MarchBy Business WireFeb 26, 2020 4:05 PM EST
PRESS RELEASESExelixis Announces First 100 Patients Enrolled In Phase 3 COSMIC-311 Pivotal Trial Of Cabozantinib In Relapsed Radioiodine-Refractory Differentiated Thyroid CancerBy Business WireFeb 25, 2020 4:06 PM EST
PRESS RELEASESExelixis To Release Fourth Quarter And Full Year 2019 Financial Results On Tuesday, February 25, 2020By Business WireFeb 12, 2020 4:05 PM EST
PRESS RELEASESExelixis Announces Encouraging Results For Cabozantinib In Combination With Atezolizumab In Metastatic Castration-Resistant Prostate CancerBy Business WireFeb 10, 2020 5:00 PM EST
PRESS RELEASESExelixis Announces Webcasts Of Investor Conference Presentations In FebruaryBy Business WireFeb 6, 2020 4:05 PM EST
PRESS RELEASESExelixis Announces Partner Takeda Files New Drug Application In Japan For CABOMETYX® (cabozantinib) For Advanced Hepatocellular CarcinomaBy Business WireJan 29, 2020 2:01 AM EST
PRESS RELEASESExelixis Announces Results For Combination Of Cabozantinib And Nivolumab With Or Without Ipilimumab In Advanced Hepatocellular CarcinomaBy Business WireJan 24, 2020 7:30 AM EST
JIM CRAMERBe Prepared: Cramer's 'Mad Money' Recap (Monday 12/9/19)By Scott RuttDec 9, 2019 8:46 PM EST
JIM CRAMERCan't Keep the Winners Down: Cramer's 'Mad Money' RecapBy Scott RuttMay 9, 2019 8:36 PM EDT
JIM CRAMERCisco Systems, Sunrun, Zebra Technologies: 'Mad Money' Lightning RoundBy Scott RuttMay 9, 2019 8:25 PM EDT
JIM CRAMERFitbit, Moderna, Tilray: 'Mad Money' Lightning RoundBy Bret KenwellFeb 13, 2019 8:45 PM EST
INVESTINGExelixis Rises as Fourth-Quarter Earnings Beat EstimatesBy M. Corey GoldmanFeb 13, 2019 9:35 AM EST
JIM CRAMERBreaking Down Citigroup Earnings: Cramer's 'Mad Money' RecapBy Scott RuttJan 14, 2019 8:59 PM EST
MARKETSBiotech Stocks Post Double-Digit Gains in Monday SurgeBy Scott Van VoorhisJan 7, 2019 6:49 PM EST
JIM CRAMERTech Doesn't Have Good Defense: Cramer's 'Mad Money' RecapBy Scott RuttOct 24, 2018 11:04 PM EDT
JIM CRAMERUnited Parcel Service, TJX Companies: 'Mad Money' Lightning RoundBy Scott RuttOct 24, 2018 11:04 PM EDT
JIM CRAMERSirius XM Radio, Molson Coors, MSCI: 'Mad Money' Lightning RoundBy Scott RuttJun 20, 2018 6:34 AM EDT
JIM CRAMERWho Are the Trade War Victims?: Cramer's 'Mad Money' RecapBy Scott RuttJun 20, 2018 6:24 AM EDT
JIM CRAMERWaste Management, Blackstone Group, Xilinx: 'Mad Money' Lightning RoundBy Scott RuttMay 4, 2018 6:35 AM EDT
JIM CRAMERAnthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning RoundBy Scott RuttFeb 6, 2018 6:58 AM EST
